{"id":57172,"date":"2026-02-14T16:51:00","date_gmt":"2026-02-14T08:51:00","guid":{"rendered":"https:\/\/flcube.com\/?p=57172"},"modified":"2026-02-14T16:51:01","modified_gmt":"2026-02-14T08:51:01","slug":"sino-biopharmas-benmelstobart-secures-fourth-nmpa-approval-for-stage-iii-nsclc-expanding-pd-l1-franchise-in-china","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=57172","title":{"rendered":"Sino Biopharma&#8217;s Benmelstobart Secures Fourth NMPA Approval for Stage III NSCLC \u2013 Expanding PD\u2011L1 Franchise in China"},"content":{"rendered":"\n<p><strong>Sino Biopharmaceutical Limited<\/strong> (<a href=\"https:\/\/www.google.com\/finance\/quote\/1177:HKG\">HKG: 1177<\/a>) announced that <strong>benmelstobart<\/strong>, a <strong>Category\u202f1 innovative humanized anti\u2011PD\u2011L1 monoclonal antibody<\/strong> developed by subsidiary <strong>Chia Tai Tianqing Pharmaceutical Group (CTTQ)<\/strong>, has received <strong>marketing approval<\/strong> from China\u2019s <strong>National Medical Products Administration (NMPA)<\/strong>. The new indication covers <strong>consolidation therapy for unresectable stage\u202fIII non\u2011small cell lung cancer (NSCLC)<\/strong> patients without disease progression following platinum\u2011based concurrent or sequential chemoradiotherapy, and without known EGFR mutations or ALK rearrangements.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-regulatory-milestone\">Regulatory Milestone<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Item<\/th><th>Detail<\/th><\/tr><\/thead><tbody><tr><td><strong>Agency<\/strong><\/td><td>NMPA (China)<\/td><\/tr><tr><td><strong>Approval Type<\/strong><\/td><td>Marketing approval, Category\u202f1 innovative drug<\/td><\/tr><tr><td><strong>Product<\/strong><\/td><td>Benmelstobart (humanized anti\u2011PD\u2011L1 mAb)<\/td><\/tr><tr><td><strong>New Indication<\/strong><\/td><td>Consolidation therapy for unresectable stage\u202fIII NSCLC post\u2011chemoradiotherapy<\/td><\/tr><tr><td><strong>Patient Population<\/strong><\/td><td>No EGFR mutations, no ALK rearrangements, no disease progression after platinum\u2011based CRT<\/td><\/tr><tr><td><strong>Approval Date<\/strong><\/td><td>14\u202fFeb\u202f2026<\/td><\/tr><tr><td><strong>Total China Indications<\/strong><\/td><td>4 (including ES\u2011SCLC, endometrial cancer, renal cell carcinoma)<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-drug-profile-amp-mechanism-of-action\">Drug Profile &amp; Mechanism of Action<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Molecule:<\/strong> Novel humanized <strong>anti\u2011PD\u2011L1 monoclonal antibody<\/strong><\/li>\n\n\n\n<li><strong>Mechanism:<\/strong> Blocks PD\u2011L1\/PD\u20111 interaction, restoring T\u2011cell\u2011mediated anti\u2011tumor immune response<\/li>\n\n\n\n<li><strong>Innovation:<\/strong> Category\u202f1 innovative biologic with demonstrated efficacy across multiple tumor types<\/li>\n\n\n\n<li><strong>Pipeline Position:<\/strong> Core immuno\u2011oncology asset for Sino Biopharma\u2019s expanding oncology franchise<\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-clinical-evidence-r-alps-phase-iii-trial\">Clinical Evidence \u2013 R\u2011ALPS Phase\u202fIII Trial<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Endpoint<\/th><th>Benmelstobart<\/th><th>Placebo<\/th><th>Relative Benefit<\/th><\/tr><\/thead><tbody><tr><td><strong>Median PFS (mPFS)<\/strong><\/td><td>9.69\u202fmonths<\/td><td>4.17\u202fmonths<\/td><td><strong>+5.52\u202fmonths (HR\u202f0.53)<\/strong><\/td><\/tr><tr><td><strong>Risk Reduction<\/strong><\/td><td>\u2013<\/td><td>\u2013<\/td><td><strong>47\u202f% reduction in progression or death<\/strong><\/td><\/tr><tr><td><strong>Median Follow\u2011up<\/strong><\/td><td>19.4\u202fmonths<\/td><td>19.4\u202fmonths<\/td><td>\u2013<\/td><\/tr><tr><td><strong>Safety Profile<\/strong><\/td><td>Manageable AEs, favorable tolerability<\/td><td>\u2013<\/td><td>Consistent with prior studies<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<p>The R\u2011ALPS study enrolled patients with <strong>locally advanced\/unresectable stage\u202fIII NSCLC<\/strong> who had not progressed after concurrent or sequential chemoradiotherapy. Benefits were <strong>consistent across all predefined subgroups<\/strong>, mirroring the overall population results.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-market-impact-amp-outlook\">Market Impact &amp; Outlook<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>China NSCLC Market:<\/strong> Stage\u202fIII NSCLC represents a significant unmet medical need, with limited consolidation therapy options post\u2011chemoradiotherapy.<\/li>\n\n\n\n<li><strong>Revenue Synergies:<\/strong> This fourth approval strengthens benmelstobart\u2019s positioning as a <strong>multi\u2011indication PD\u2011L1 backbone<\/strong>, enabling combination strategies with CTTQ\u2019s anlotinib and other pipeline assets.<\/li>\n\n\n\n<li><strong>Competitive Landscape:<\/strong> Benmelstobart joins a crowded PD\u2011L1\/PD\u20111 market but differentiates through its <strong>consolidation setting<\/strong> in stage\u202fIII NSCLC, a niche with strong clinical validation.<\/li>\n\n\n\n<li><strong>Pipeline Expansion:<\/strong> With approvals in ES\u2011SCLC, endometrial cancer, renal cell carcinoma, and now stage\u202fIII NSCLC, Sino Biopharma is building a <strong>comprehensive immuno\u2011oncology portfolio<\/strong> targeting China\u2019s largest cancer indications.<\/li>\n<\/ul>\n\n\n\n<p><strong>Forward\u2011Looking Statements<\/strong><br>This brief contains forward\u2011looking statements regarding regulatory approvals, clinical outcomes, and commercial expectations for benmelstobart. Actual results may differ due to risks including market competition, reimbursement negotiations, and physician adoption rates.<a href=\"https:\/\/flcube.com\/\">-Fineline Info &amp; Tech<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Sino Biopharmaceutical Limited (HKG: 1177) announced that benmelstobart, a Category\u202f1 innovative humanized anti\u2011PD\u2011L1 monoclonal antibody&#8230;<\/p>\n","protected":false},"author":1,"featured_media":57173,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7,11],"tags":[661,908,18,15,313],"class_list":["post-57172","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-company","category-drug","tag-chia-tai-tianqing-pharmaceutical","tag-hkg-1177","tag-pd-1-l1","tag-product-approvals","tag-sino-biopharmaceutical"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v27.5 (Yoast SEO v27.6) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>Sino Biopharma&#039;s Benmelstobart Secures Fourth NMPA Approval for Stage III NSCLC \u2013 Expanding PD\u2011L1 Franchise in China - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"Sino Biopharmaceutical Limited (HKG: 1177) announced that benmelstobart, a Category\u202f1 innovative humanized anti\u2011PD\u2011L1 monoclonal antibody developed by subsidiary Chia Tai Tianqing Pharmaceutical Group (CTTQ), has received marketing approval from China\u2019s National Medical Products Administration (NMPA). The new indication covers consolidation therapy for unresectable stage\u202fIII non\u2011small cell lung cancer (NSCLC) patients without disease progression following platinum\u2011based concurrent or sequential chemoradiotherapy, and without known EGFR mutations or ALK rearrangements.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=57172\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Sino Biopharma&#039;s Benmelstobart Secures Fourth NMPA Approval for Stage III NSCLC \u2013 Expanding PD\u2011L1 Franchise in China\" \/>\n<meta property=\"og:description\" content=\"Sino Biopharmaceutical Limited (HKG: 1177) announced that benmelstobart, a Category\u202f1 innovative humanized anti\u2011PD\u2011L1 monoclonal antibody developed by subsidiary Chia Tai Tianqing Pharmaceutical Group (CTTQ), has received marketing approval from China\u2019s National Medical Products Administration (NMPA). The new indication covers consolidation therapy for unresectable stage\u202fIII non\u2011small cell lung cancer (NSCLC) patients without disease progression following platinum\u2011based concurrent or sequential chemoradiotherapy, and without known EGFR mutations or ALK rearrangements.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=57172\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2026-02-14T08:51:00+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-02-14T08:51:01+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/02\/1406.webp\" \/>\n\t<meta property=\"og:image:width\" content=\"1080\" \/>\n\t<meta property=\"og:image:height\" content=\"608\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=57172#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=57172\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"Sino Biopharma&#8217;s Benmelstobart Secures Fourth NMPA Approval for Stage III NSCLC \u2013 Expanding PD\u2011L1 Franchise in China\",\"datePublished\":\"2026-02-14T08:51:00+00:00\",\"dateModified\":\"2026-02-14T08:51:01+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=57172\"},\"wordCount\":425,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=57172#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2026\\\/02\\\/1406.webp\",\"keywords\":[\"Chia Tai Tianqing Pharmaceutical\",\"HKG: 1177\",\"PD-1\\\/L1\",\"Product approvals\",\"Sino Biopharmaceutical\"],\"articleSection\":[\"Company\",\"Drug\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=57172#respond\"]}],\"copyrightYear\":\"2026\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=57172\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=57172\",\"name\":\"Sino Biopharma's Benmelstobart Secures Fourth NMPA Approval for Stage III NSCLC \u2013 Expanding PD\u2011L1 Franchise in China - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=57172#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=57172#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2026\\\/02\\\/1406.webp\",\"datePublished\":\"2026-02-14T08:51:00+00:00\",\"dateModified\":\"2026-02-14T08:51:01+00:00\",\"description\":\"Sino Biopharmaceutical Limited (HKG: 1177) announced that benmelstobart, a Category\u202f1 innovative humanized anti\u2011PD\u2011L1 monoclonal antibody developed by subsidiary Chia Tai Tianqing Pharmaceutical Group (CTTQ), has received marketing approval from China\u2019s National Medical Products Administration (NMPA). The new indication covers consolidation therapy for unresectable stage\u202fIII non\u2011small cell lung cancer (NSCLC) patients without disease progression following platinum\u2011based concurrent or sequential chemoradiotherapy, and without known EGFR mutations or ALK rearrangements.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=57172#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=57172\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=57172#primaryimage\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2026\\\/02\\\/1406.webp\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2026\\\/02\\\/1406.webp\",\"width\":1080,\"height\":608,\"caption\":\"Sino Biopharma's Benmelstobart Secures Fourth NMPA Approval for Stage III NSCLC \u2013 Expanding PD\u2011L1 Franchise in China\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=57172#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Sino Biopharma&#8217;s Benmelstobart Secures Fourth NMPA Approval for Stage III NSCLC \u2013 Expanding PD\u2011L1 Franchise in China\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Sino Biopharma's Benmelstobart Secures Fourth NMPA Approval for Stage III NSCLC \u2013 Expanding PD\u2011L1 Franchise in China - Insight, China&#039;s Pharmaceutical Industry","description":"Sino Biopharmaceutical Limited (HKG: 1177) announced that benmelstobart, a Category\u202f1 innovative humanized anti\u2011PD\u2011L1 monoclonal antibody developed by subsidiary Chia Tai Tianqing Pharmaceutical Group (CTTQ), has received marketing approval from China\u2019s National Medical Products Administration (NMPA). The new indication covers consolidation therapy for unresectable stage\u202fIII non\u2011small cell lung cancer (NSCLC) patients without disease progression following platinum\u2011based concurrent or sequential chemoradiotherapy, and without known EGFR mutations or ALK rearrangements.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=57172","og_locale":"en_US","og_type":"article","og_title":"Sino Biopharma's Benmelstobart Secures Fourth NMPA Approval for Stage III NSCLC \u2013 Expanding PD\u2011L1 Franchise in China","og_description":"Sino Biopharmaceutical Limited (HKG: 1177) announced that benmelstobart, a Category\u202f1 innovative humanized anti\u2011PD\u2011L1 monoclonal antibody developed by subsidiary Chia Tai Tianqing Pharmaceutical Group (CTTQ), has received marketing approval from China\u2019s National Medical Products Administration (NMPA). The new indication covers consolidation therapy for unresectable stage\u202fIII non\u2011small cell lung cancer (NSCLC) patients without disease progression following platinum\u2011based concurrent or sequential chemoradiotherapy, and without known EGFR mutations or ALK rearrangements.","og_url":"https:\/\/flcube.com\/?p=57172","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2026-02-14T08:51:00+00:00","article_modified_time":"2026-02-14T08:51:01+00:00","og_image":[{"width":1080,"height":608,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/02\/1406.webp","type":"image\/png"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=57172#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=57172"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"Sino Biopharma&#8217;s Benmelstobart Secures Fourth NMPA Approval for Stage III NSCLC \u2013 Expanding PD\u2011L1 Franchise in China","datePublished":"2026-02-14T08:51:00+00:00","dateModified":"2026-02-14T08:51:01+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=57172"},"wordCount":425,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"image":{"@id":"https:\/\/flcube.com\/?p=57172#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/02\/1406.webp","keywords":["Chia Tai Tianqing Pharmaceutical","HKG: 1177","PD-1\/L1","Product approvals","Sino Biopharmaceutical"],"articleSection":["Company","Drug"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=57172#respond"]}],"copyrightYear":"2026","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=57172","url":"https:\/\/flcube.com\/?p=57172","name":"Sino Biopharma's Benmelstobart Secures Fourth NMPA Approval for Stage III NSCLC \u2013 Expanding PD\u2011L1 Franchise in China - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/flcube.com\/?p=57172#primaryimage"},"image":{"@id":"https:\/\/flcube.com\/?p=57172#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/02\/1406.webp","datePublished":"2026-02-14T08:51:00+00:00","dateModified":"2026-02-14T08:51:01+00:00","description":"Sino Biopharmaceutical Limited (HKG: 1177) announced that benmelstobart, a Category\u202f1 innovative humanized anti\u2011PD\u2011L1 monoclonal antibody developed by subsidiary Chia Tai Tianqing Pharmaceutical Group (CTTQ), has received marketing approval from China\u2019s National Medical Products Administration (NMPA). The new indication covers consolidation therapy for unresectable stage\u202fIII non\u2011small cell lung cancer (NSCLC) patients without disease progression following platinum\u2011based concurrent or sequential chemoradiotherapy, and without known EGFR mutations or ALK rearrangements.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=57172#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=57172"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/?p=57172#primaryimage","url":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/02\/1406.webp","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/02\/1406.webp","width":1080,"height":608,"caption":"Sino Biopharma's Benmelstobart Secures Fourth NMPA Approval for Stage III NSCLC \u2013 Expanding PD\u2011L1 Franchise in China"},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=57172#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"Sino Biopharma&#8217;s Benmelstobart Secures Fourth NMPA Approval for Stage III NSCLC \u2013 Expanding PD\u2011L1 Franchise in China"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/02\/1406.webp","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/57172","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=57172"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/57172\/revisions"}],"predecessor-version":[{"id":57174,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/57172\/revisions\/57174"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/media\/57173"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=57172"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=57172"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=57172"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}